What happened with SPRC today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
SciSparc Ltd. is a clinical-stage drug developer whose pharmaceutical candidates have not yet earned sales revenue. It transferred its advanced clinical-stage portfolio and its stake in SciSparc Nutraceuticals to NeuroThera, which it controls. Much of its drug development now runs through NeuroThera, making that company’s progress and funding needs central to SciSparc’s business.
Customers currently pay for Wellution hemp-based products sold by SciSparc Nutraceuticals on Amazon Marketplace. This business supplies the company’s sales revenue and depends on access to Amazon and outside product suppliers; a temporary removal of Wellution from the marketplace disrupted sales. Drug development, by contrast, depends on money raised from investors rather than pharmaceutical sales.
The pharmaceutical programs include SCI-110 for Tourette syndrome. Turning candidates into products requires successful trials, regulatory approval and outside manufacturing. None has pharmaceutical marketing approval, and controlled-substance candidates also need U.S. Drug Enforcement Administration scheduling clearance before sale. SciSparc has also acquired Xylo’s intellectual-property portfolio associated mainly with the MUSE endoscopic system and medical cameras, which it plans to commercialize.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
SciSparc’s results increasingly depend on its controlling investment in NeuroThera, which holds its transferred clinical portfolio and Wellution stake, making NeuroThera’s financing and regulatory progress key to watch.
SciSparc depends on Clearmind Medicine Inc.’s consent to use their jointly owned intellectual property for drug combinations pairing SciSparc’s CannAmide with psychedelic compounds, including Clearmind’s MEAI. Progress toward commercial-use rights for these combinations matters because shared ownership can constrain SciSparc’s drug development and commercialization.
Polyrizon Ltd.’s progress developing pain treatments with SciSparc’s licensed SCI-160 technology can bring SciSparc milestone payments, sales royalties and a share of sublicensing proceeds. The nasal-gel developer has reported no revenue, so SCI-160 development and regulatory milestones—worth up to $3.32 million to SciSparc—are a more immediate item to watch than product sales.
Nexera Technologies Ltd manages SciSparc’s Wellution brand for a fee and holds a minority stake in its owner, alongside running its own Amazon consumer-product businesses. Watch Wellution’s availability on Amazon: its hemp-based product sales generated all SciSparc revenue in 2025, and a temporary removal from the marketplace contributed to the revenue decline.
SciSparc participates in Nexentis Technologies Inc.’s fortunes through the 16.75% equity stake it received at closing for selling MitoCareX, whose software models proteins that transport substances within mitochondria. Watch the specified development milestones: meeting them by December 31, 2028 can earn SciSparc additional Nexentis shares.
Incannex Healthcare Limited’s clinical progress offers a reference for SciSparc’s development strategy because both pursue cannabinoid combinations and psychedelic treatments. Watch clinical results from those treatments for evidence supporting these approaches.
Helus Pharma Inc. offers a development comparison for SciSparc: Helus develops novel mental-health medicines that act on serotonin receptors, while SciSparc pursues psychedelic combination therapies with Clearmind. Its progress in developing these medicines provides context for SciSparc’s own approach, rather than a direct source of revenue.
Helus Pharma Inc. earningsHELP
Helus develops novel medicines that act on serotonin receptors, and its report offers context for the development environment around SciSparc and Clearmind’s psychedelic-combination therapies.
Read Helus’s reported development progress alongside its research spending. Clear progress shows that novel mental-health medicines are advancing and provides context for SciSparc’s own development path; spending without much progress highlights the funding burden such work can carry. Their drug approaches differ, so Helus’s results cannot establish that SciSparc’s therapies work.
Incannex Healthcare Limited earningsIXHL
Incannex is also developing cannabinoid combinations and psychedelic treatments, so its clinical progress gives context for SciSparc’s work in similar areas.
Look for reported clinical progress in Incannex’s cannabinoid-combination or psychedelic programs. Clear progress shows that these research approaches are advancing and offers a reference point for SciSparc’s strategy; limited progress or delays underline that shared treatment areas do not remove clinical, regulatory or funding hurdles. Incannex’s results do not substitute for SciSparc’s own trial data.
Nexentis Technologies Inc. earningsNXTS
SciSparc owns a 16.75% stake in Nexentis, whose report may show progress toward MitoCareX-related milestones that could earn SciSparc additional shares under the sale terms.
Look for Nexentis’s reported progress on the specified development milestones and compare it with the sale terms: meeting them by December 31, 2028 can earn SciSparc additional Nexentis shares; if they are not met, those additional shares are not earned. Nexentis’s progress is not progress in SciSparc’s own drug development.
